Mylan pricked into EpiPen price cut

Clinton among critics to slam cost of anaphylactic shock treatment

©Epipen Media Room

Mylan: pen is not mightier

Drug group has yet to justify the pricing on Epipen

Brexit offers opportunities to UK science

Britain needs light touch regulation similar to Switzerland to be global leader, writes John Bell

Breast cancer test raises hope of avoiding chemo

Genetic check may help early-stage patients avoid toxic follow-up

Clinton and White House join Mylan furore

Democratic nominee urges cut in ‘outrageous’ price of EpiPen

Pfizer snaps up AstraZeneca antibiotics

Anglo-Swedish drugmaker says $1.6bn sale will allow it to concentrate on core areas

Pfizer looks to conquer cancer with deal

Drugmaker’s $14bn deal is part of strategy to lead in oncology

Pfizer makes $14bn bet on cancer drugs

Bid for Medivation to build position as leader in oncology

Pfizer/Medivation: combination therapy

Pfizer must hope for performance that justifies the premium paid

Pfizer nears $14bn takeover of Medivation

US drug company set to win auction for California biotech group

Pharmaceuticals: Staying power

FT analysis shows big pharma makes billions after patents lapse

US doctors waste millions on branded drugs

Big pharma groups make more than $1bn in six months as cheap generics overlooked by prescribers

Stada faces showdown with activist

AOC seeks to clear out German generic drugmaker’s board

T Rowe Price accuses Valeant of vast fraud

Fund manager alleges chiefs wiped out billions of dollars in value

Gilead: breaking the fever

It is better to be cheap than stupid

The rise and fall of German internet star

Tale of Thomas Wagner’s last days reads like a detective novel

Samsung biopharma unit lines up IPO

Biologics listing expected to raise Won2tn-Won3tn

Valeant: follow the money

Sales trends, not legal investigations, are the key

Novartis faces possible S Korea sales ban

Prosecutors seek suspension of some medicines sold by Swiss group amid illegal rebates probe

The Zika virus — the long-term prognosis

Research is gathering pace as mosquito-borne disease spreads


More FT Twitter accounts